Submit Your Feeds

Business News • PR NewsWire • Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases

Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases
Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases

GHENT, Belgium and NORTH CHICAGO, Ill., Sept. 23, 2013 /PRNewswire/ -- Ablynx [Euronext Brussels: ABLX] and AbbVie [NYSE: ABBV] today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat...

View More : http://www.prnewswire.com/news-releases/ablynx-and-abbvie-sign-global-license-agreement-for-anti-il-6r-nanobody-alx-0061...
Releted News by prnewswire
65th Annual Primetime Emmy Award Nominees Shine in Forevermark Diamonds
Pommes-Verkaufsautomat: eine neue Ära für die Zubereitung von Pommes frites
Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases
Huawei Announces an Integrated Data Integrity Solution in Collaboration with Emulex and Oracle
Home Sitemap Contact Us
© businessNewsNewsNews.com